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Abstract
BACKGROUND
Establishing a diagnosis of pancreatic cystic lesions (PCLs) preoperatively still
remains challenging. Recently, endoscopic ultrasound (EUS)-through-the-needle
biopsy (EUS-TTNB) using microforceps in PCLs has been made available.
AIM
To assess the efficacy and safety of EUS-TTNB in the diagnosis of PCLs.
METHODS
We retrospectively collected data of patients with PCLs who underwent both
EUS-fine-needle aspiration (FNA) for cytology and EUS-TTNB at our institution
since 2016. EUS-FNA for cytology was followed by EUS-TTNB in the same
session. Evaluation of the cyst location, primary diagnosis, adverse events, and
comparison between the cytologic fluid analyses and histopathology was
performed. Technical success of EUS-TTNB was defined as visible tissue present
after biopsy. Clinical success was defined as the presence of a specimen adequate
to make a histologic or cytologic diagnosis.
RESULTS
A total of 56 patients (mean age 66.9 ± 11.7, 53.6% females) with PCLs were
enrolled over the study period. The mean cyst size was 28.8 mm (12-85 mm). The
EUS-TTNB procedure was technically successful in all patients (100%). The
clinical success rate using EUS-TTNB was much higher than standard EUS-FNA,
respectively 80.4% (45/56) vs 25% (14/56). Adverse events occurred in 2 patients
(3.6%) who developed mild pancreatitis that resolved with medical therapy.
Using TTNB specimens, 23 of 32 cases (71.9%) with intraductal papillary
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mucinous neoplasm were further differentiated into gastric type (19 patients) and
pancreaticobiliary type (4 patients) based on immunochemical staining.
CONCLUSION
EUS-TTNB for PCLs was technically feasible and had a favorable safety profile.
Furthermore, the diagnostic yield for PCLs was much higher with EUS-TTNB
than standard EUS-FNA cytology and fluid carcinoembryonic antigen. EUS-
TTNB should be considered as an adjunct to EUS-FNA and cytologic analysis in
the diagnosis and management of PCLs.
Key words: Pancreatic cyst lesion; Endoscopic ultrasound; Endoscopic ultrasound-guided
fine needle aspiration; Cyst fluid; Biopsy
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Establishing a diagnosis of pancreatic cystic lesions (PCLs) preoperatively still
remains a challenge. Endoscopic ultrasound (EUS)-through-the-needle biopsy (EUS-
TTNB) using microforceps was recently used to make a definitive diagnosis of PCLs.
The aim of this study was to assess the safety and efficacy of EUS-TTNB compared with
EUS-fine-needle aspiration (FNA), and feasibility of intrapapillary mucinous neoplasm
(IPMN) subtyping using EUS-TTNB specimen. Fifty-six patients underwent EUS-
TTNB. The rates of technical success, clinical success, and adverse events were 100%,
80.4% and 3.6%, respectively. The clinical success rate was higher in EUS-TTNB
(80.4%) than in EUS-FNA (15%). IPMN subtyping was successful in 71.9% (23/32) in
patients with IPMN.
Citation: Hashimoto R, Lee JG, Chang KJ, Chehade NEH, Samarasena JB. Endoscopic
ultrasound-through-the-needle biopsy in pancreatic cystic lesions: A large single center
experience. World J Gastrointest Endosc 2019; 11(11): 531-540
URL: https://www.wjgnet.com/1948-5190/full/v11/i11/531.htm
DOI: https://dx.doi.org/10.4253/wjge.v11.i11.531
INTRODUCTION
Establishing  a  diagnosis  of  pancreatic  cystic  lesions  (PCLs)  preoperatively  still
remains challenging. PCLs are discovered more often than before as a result of the
widespread use of highresolution imaging techniques[1]. The prevalence of the PCLs is
reported from 2.4% to 13.5% with increasing incidence with age[2]. The incidence of
PCLs has been reported in 12.9% in a population-based study over a period of 5-year
follow-up[3].  Some  PCLs  have  the  potential  for  malignant  transformation  to
adenocarcinoma  of  the  pancreas.  On  the  other  hand,  the  rate  of  malignant
transformation is low in general[4] and is estimated approximately 0.24% per year[5].
The assessment of the risk of malignant transformation relies on information such as
clinical history, results of radiological examinations, endoscopic ultrasound (EUS),
cystic fluid analysis, and cytohistological testing. However, no single diagnostic tool
has been found to be reliable for the differential diagnosis of PCLs.
EUS-fine  needle  aspiration  (FNA)  improves  diagnostic  accuracy  in  PCLs  for
differentiating mucinous versus non-mucinous PCLs, and malignant versus benign
PCLs,  in cases where computed tomography or magnetic resonance imaging are
unclear. Evaluation of cyst fluid carcinoembryonic antigen (CEA), combined with
cytology is  often used for differentiating an IPMN or mucinous cystic  neoplasm
(MCN) from other PCLs. A recent meta-analysis showed EUS-FNA-based cytology
had 42% sensitivity and 99% specificity to differentiate mucinous from non-mucinous
pancreatic cystic neoplasm[6]. A cyst fluid CEA level of ≥ 192ng/mL can distinguish
mucinous, from non-mucinous cysts, with a sensitivity of 52%-78%and specificity of
63-91%[7-13]. In two meta-analysis, EUS-FNA-based cytology showed a sensitivity of
51% and specificity of 94% for the diagnosis of malignant PCLs[14] and CEA seems not
accurate to predict malignancy with sensitivity and specificity of 63%[15]. Targeted cyst
wall sampling using FNA can provide adequate specimen for cytologic or histologic
evaluation in 65%-81% and offer additional diagnostic yield for mucinous cyst over
fluid analysis/cytology alone[16-18]. However, the diagnostic yield remains not enough
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high due to the relatively small tissue sample that can be obtained using conventional
FNA.
Recently, EUS-through-the-needle biopsy (EUS-TTNB) using microforceps (Figure
1; MorayTM microforceps, US Endoscopy, OH, United States) in PCLs has been made
available[19-27]. This method can provide a fragment of the cyst wall improving the
diagnostic yield. However, there still remains limited data regarding the efficacy and
its safety profile. The aim of this study is to evaluate EUS-TTNB in terms of diagnostic
yield and safety in the diagnosis of PCLs. A secondary aim is to evaluate the additive
value in diagnostic yield over standard EUS-FNA.
MATERIALS AND METHODS
Patient selection
We retrospectively reviewed all of the patients with PCLs who had EUS-FNA and
EUS-TTNB at our institution between Jan 2016 and November 2018 using electronic
endoscopy database. The indication of EUS-TTNB was judged by the endoscopists
based  on  clinical  background,  size,  radiologic  imaging  findings,  existence  of
worrisome features like solid mass or nodule, and patient anxiety. This study protocol
was approved by the University of California Irvine Medical Center Institutional
Review Board.
Data collection
Patients demographics, radiologic imaging, endoscopy imaging, cyst fluid analysis,
cytology and pathology results were reviewed. Follow-up data were obtained from
clinical encounters or telephone interview after the procedure to discuss pathology
results.  Continuous  variables  were  reported  as  median  and  range.  Categorical
variables were summarized as frequency and percentage.
Aims
The aim of this study was to assess the feasibility and safety of EUS-TTNB for PCLs,
and evaluate the diagnostic yield compared with EUS-FNA.
Definitions
Technical success of EUS-TTNB was defined as visible tissue present after biopsy.
Clinical  success  was  defined as  the  presence  of  a  specimen adequate  to  make a
histologic or cytologic diagnosis. Safety was assessed by recording adverse events
following American Society  for  Gastrointestinal  Endoscopy Criteria.  PCLs were
classified  as  mucinous  cysts  (intraductal  papillary  mucinous  neoplasms  and
mucinous cystic neoplasms), serous cystadenomas, or benign and/or inflammatory
cysts  (pseudocysts)  based  on  cytology,  pathology,  and  cyst  fluid  analysis.  The
histology evaluation of the TTNB specimen followed standard histology definitions
for  epithelial  type.  For  diagnosis  of  mucinous  cyst,  mucinous  epithelium  with
cytoplasmic mucin should be visible on routine hematoxylin and eosin stain. The
presence of subepithelial ovarian type stroma defined an MCN, and the absence of
such  stroma  defined  an  IPMN.  If  the  diagnosis  of  IPMN  was  established,  the
expression  of  MUC1,  MUC2,  MUC5AC,  MUC6  mucins  were  evaluated
immunohistochemically for subtyping, if it was feasible.
Procedure
Three endosonographers performed or supervised all  the EUS-TTNB procedures.
Prophylactic antibiotics (Cefazolin 1g) were administered to all patients before needle
puncture  of  PCLs.  All  the  procedures  were  performed  by  using  a  linear
echoendoscope  (Olympus  America,  Center  Valley,  PA,  United  States).  Careful
evaluation was done for cyst location, size and presence of a mural nodule, solid mass
or wall thickness. EUS-FNA was performed using the 19-gauge EUS-FNA needle
(EchoTip Ultra needle; Cook Medical, Bloomington, IN, United States) with a stylet.
Before puncturing PCLs, the stylet was removed and the microforceps was preloaded
in the FNA needle. The needle was inserted into the PCL under EUS guidance and
with the use of Doppler to avoid interposed vessels.  After puncturing PCLs,  the
microforceps was inserted through the bore of the FNA needle. Once the forceps was
seen within the cyst, the forceps was opened and the open jaws of the forceps were
retracted and hubbed to the end of the needle (Figure 2). The needle with forceps
open were then advanced using the FNA needle handle and gently pushed against
the opposite walls, then closed and pulled back until the ‘tent sign’ was seen (Figure
3). Finally, the microforceps was pulled back inside the needle, and the specimen
obtained was placed directly in formalin. In this manner, three to four passes were
made with microforceps. After completion of biopsies, cyst fluid was aspirated and
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Figure 1
Figure 1  Image of MorayTM microforceps (US Endoscopy, OH, United States).
sent for CEA and cytology. A minimum of 1 mL of intracystic fluid was aspirated and
sent  for  CEA  and  amylase  level.  An  experienced  pathologist  evaluated  all  the
specimen and cytology. If IPMN was suspected, immunostaining was performed to
determine  the  subtype.  After  the  procedure,  patients  were  followed up for  any
possible adverse events including abdominal pain, pancreatitis, or perforation.
Statistical analysis
In order to describe the patient cohort, descriptive statistical analyses were used, such
as means, standard deviations, percentages, and frequency distribution, based on the
nature of the statistical variables reported in the study. The value of P < 0.05 was
considered statistically significant. Statistical analyses were done with R software
(version 3.3.3; The R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Patient demographics, and clinical features of the PCLs are shown in Table 1. A total
of 56 patients (mean age 66.9 ± 11.7, 53.6% females) with PCLs were enrolled over the
study period. The mean cyst size was 28.8 mm (12-85 mm). Cysts were in the uncinate
(4  patients),  head (13),  neck (16),  body (7)  and tail  (16).  The  average  number  of
biopsies taken during EUS-TTNB was 3.14 per patient.
Technical and clinical success
The EUS-TTNB procedure was technically  successful  in  all  patients  (100%).  The
clinical success rate using EUS-TTNB was much higher than standard EUS-FNA,
respectively 80.4% (45/56) vs  25% (14/56).  The results of histology confirmed by
TTNB is shown in Table 2. There was one case of neuroendocrine tumor that was
diagnosed  by  TTNB,  which  was  not  demonstrated  by  cytologic  analysis.  TTNB
changed  the  diagnosis  in  one  patient  from  mucinous  cystadenoma  to  serous
cystadenoma. TTNB made a diagnosis  of  adenocarcinoma in two cases.  The one
seemed to arise from IPMN and the other seemed to be cystic adenocarcinoma. Both
cases were un-resectable.
Cyst fluid analysis
Fluid CEA analysis was available in 38/56 PCLs (67.9%). For the 25 PCLs with CEA <
192 ng/mL indicating a non-mucinous cyst, TTNB provided a diagnosis of mucinous
cyst in 13/25 (52%) cases while EUS FNA provided a mucinous cyst diagnosis in 3/25
(12%) cases (P < 0.01). For 13 PCLs with CEA > 192 ng/mL, 10 PCLs (76.9%) were
diagnosed  as  mucinous  cyst  based  on  TTNB  histology  while  EUS-FNA  gave  a
mucinous cyst diagnosis in 2/13 (15.4%) (P < 0.01) (Table 3).
Subtype of IPMN
Using TTNB specimens and immunostaining, 23 cases (71.9%) among 32 cases of
intraductal papillary mucinous neoplasm were further differentiated into gastric type
(19 patients) and pancreatico-biliary type (4 patients) based on histological assessment
and immunohistochemical staining.
Correlation between EUS-TTNB and surgical specimen
Four patients had surgery after EUS-TTNB in our case series. In three of four cases,
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Figure 2
Figure 2  Endosonographic image of the microforceps opened within a pancreatic cystic lesion.
the diagnosis based on EUS-TTNB was the same as the one on surgical specimen. In
one case, EUS-TTNB diagnosis was pancreato-biliary type IPMN, although it changed
to gastric type IPMN on the surgical specimen.
Adverse events
Two patients (3.6%) developed acute pancreatitis after EUS-TTNB. Both patients were
treated with supportive care and were discharged within 2 d without any invasive
intervention.
DISCUSSION
EUS is useful in the diagnostic evaluation and estimating malignant potential of PCLs.
EUS-FNA of PCLs is a well-established procedure and gives rise to information such
as cytology and intracystic fluid marker analysis, to assist in differentiating mucinous
from non-mucinous lesions. Differentiating PCLs is very important because SCAs do
not require surgery, while on the other hand, MCNs need to be resected. However,
the  diagnostic  accuracy of  cytology and fluid markers  such as  CEA are  still  not
enough high. Cyst fluid molecular analysis seemed promising but has issues with cost
and availability[6,12,28,29]). Some studies have shown that EUS-guided confocal laser
endomicroscopy could be helpful but inter-observer agreement is very variable[30,31].
EUS-TTNB is a straightforward procedure and some case series have already shown
promising outcomes[20-27].
Our study results showed 100% technical success and 80.4% of clinical success,
which are very similar to previous case series study[20-23,25-27]. In our study, 13 of 25
cysts with CEA < 192 ng/mL ended up having the diagnosis of mucinous cyst based
on EUS-TTNB specimen. This result confirmed that fluid analysis for CEA is not
reliable  for  differentiation  of  a  mucinous  cyst  and  non-mucinous  cyst  at  our
institution. EUS-TTNB demonstrated higher accuracy in providing the diagnosis of a
mucinous cyst than EUS-FNA based cytology regardless of the value of CEA. This
suggests EUS-TTNB is likely superior to the current standard of EUS-FNA cytology
combined with fluid CEA analysis for detection of mucinous cysts.
With regards to complications, 2/56 patients (3.6%) developed acute pancreatitis
after EUS-TTNB. Based on previous studies, the complications after this procedure are
usually acute pancreatitis  and local  bleeding from the biopsy site.  In the largest
multicenter study of EUS-TTNB study with 114 patients[26], pancreatitis occurred in 6
patients (5.3%). pancreatitis occurred in 6 patients (5.3%). This study contained one
patient with severe acute pancreatitis who required cystogastrostomy for pseudocyst.
In our study, pancreatitis in both patients were self-limited and mild.
In contrast  to previous studies on TTNB, our institution attempted to subtype
IPMN using the EUS-TTNB specimen. Several studies have suggested the histologic
subtype of IPMN may be an important factor in its natural history. Studies have
indicated in particular that the pancreaticobiliary subtype of IPMN may be associated
with a poor prognosis[32,33] although this is controversial[34]. Using a combination of
histologic analysis and immunohistochemical staining, we were successfully able to
subtypes the majority of IPMNs in our series. Subtyping using EUS-TTNB may be
helpful to decide how to follow the IPMN without resection. Our study is the first
study indicating that subtype of IPMN with EUS-TTNB can be reproducible. In one
surgical case, IPMN subtype based on EUS-TTNB was not consistent with that based
on the surgical specimen. In this particular case, the surgical specimen was a mixed
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Figure 3
Figure 3  Endosonographic image of the microforceps bite of the wall tenting tissue within a pancreatic
cystic lesion.
subtype and we do need to keep in mind that IPMN subtype based on EUS-TTNB
may not represent the predominant subtype of the entire PCL in some cases.
Our study has several limitations. First, this is a single center, retrospective study.
Secondly, the number of enrolled patients is relatively low, although this is the largest
study at a single center study to our knowledge using a standardized technique.
Lastly, we cannot conclude the correlation between TTNB specimen and surgical
specimen because only 4 patients had surgery after EUS-TTNB in this cohort.
In conclusion, EUS-TTNB for PCLs was technically feasible and had a favorable
safety profile in this study. Furthermore, the diagnostic yield for PCLs was much
higher with EUS-TTNB than standard EUS-FNA cytology and fluid CEA. EUS-TTNB
should  be  considered  as  an  adjunct  to  EUS-FNA  and  cytologic  analysis  in  the
diagnosis and management of PCLs.
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Table 1  Patient characteristics
Patient characteristics
Age, mean ± SD, yr 66.9 ± 11.7
Sex, male/female 26/30
Cyst size, mm 28.8 (12-85)
Location
Uncinate 4
Head 13
Neck 16
Body 7
Tail 16
Biopsy times 3.14 (1-6)
Pre-biopsy clinical diagnosis
Intraductal papillary mucinous neoplasm 31
Unknown 18
Pseudocyst 5
Mucinous cystadenoma 1
Neuroendocrine tumor 1
Table 2  Results of endoscopic guided through the needle biopsy
Technical success 100% (56/56)
Clinical success 80.4% (45/56)
Adverse events 3.6% (2/56)
Histopathological diagnosis by EUS-TTNB
IPMN 32
Pseudocyst 4
Serous cyst neoplasm 4
Neuroendocrine tumor 2
Adenocarcinoma 2
Paraganglioma 1
Inconclusive 11
Subtyping of IPMN (n = 32)
Gastric type 19
Pancreatobiliary type 4
Inconclusive 9
IPMN: Intraductal papillary mucinous neoplasm; EUS-TTNB: Endoscopic ultrasound-through-the-needle biopsy.
Table 3  Comparison between endoscopic ultrasound-fine-needle aspiration and endoscopic ultrasound-through-the-needle biopsy
EUS-FNA EUS-TTNB P value
Clinical success 25% (14/56) 80.4% (45/56) < 0.001
Mucinous cyst diagnosis in cysts > CEA 192 ng/mL 12% (3/25) 52% (13/25) 0.005
Mucinous cyst diagnosis in cysts < CEA 192 ng/mL 15.4% (2/13) 76.9% (10/13) 0.005
EUS-FNA: Endoscopic ultrasound-fine-needle aspiration; EUS-TTNB: Endoscopic ultrasound-through-the-needle biopsy; CEA: Carcinoembryonic antigen.
ARTICLE HIGHLIGHTS
Research background
Pancreatic  cysts  are increasingly being identified in asymptomatic  patients.  Establishing a
diagnosis of pancreatic cystic lesions (PCLs) preoperatively still remains a challenge. Endoscopic
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ultrasound (EUS)-fine-needle aspiration (FNA) showed high specificity in diagnosing mucinous
cysts and high grade atypia. However, the sensitivity is not enough high because of relatively
acellular samples. Recently, EUS-through-the-needle biopsy (EUS-TTNB) using microforceps
was  recently  used to  make  a  definitive  diagnosis  of  PCLs.  There  have  been  some studies
showing the efficacy and safety of EUS-TTNB for PCLs.
Research motivation
The number of studies describing the safety and efficacy of EUS-TTNB is still small. There have
been no study evaluating the feasibility of intraductal papillary mucinous neoplasm (IPMN)
subtyping using EUS-TTNB specimen.
Research objectives
The aim of this study was to evaluate the safety and efficacy of EUS-TTNB, compare the tissue
acquisition and diagnostic tissue yield of EUS-TTNB with EUS-FNA, and assess the feasibility of
IPMN subtyping using EUS-TTNB specimen.
Research methods
A retrospective analysis of endoscopy reporting system and medical records of patients who
underwent  EUS-TTNB for  PCLs was conducted.  The review and analysis  were  conducted
through our endoscopy reporting system (endoPRO iQ®) and medical records.
Research results
A total  of  56 patients with PCLs were included.  The clinical  success rate using EUS-TTNB
(80.4%) was much higher than EUS-FNA (25%). Adverse events occurred only in 2 patients
(3.6%) who developed mild pancreatitis that resolved with medical therapy. Subtyping of IPMN
was successful in 23 of 32 cases (71.9%) using TTNB specimens.
Research conclusions
EUS-TTNB is a safe and feasible procedure for evaluation of PCLs. The clinical success rate was
higher in EUS-TTNB than in EUS-FNA. IPMN subtype was also possible in many cases.
Research perspectives
Given recent development of genetic mutation analysis of PCLs, risk stratification using EUS-
TTNB specimen might be possible in the future.
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